UnitedHealth Group beat Q2 2026 earnings estimates by roughly 30%, its medical cost ratio dropped to a two-year low, and the stock jumped as much as 7.6% before settling into a smaller, but still real, gain by the close. Options traders had priced in a 6.1% to 6.27% move heading into the July 16 report, below UNH’s own trailing four-quarter average swing of about 9%. What actually happened split the difference in an instructive way: the print-day move came in under the priced expected move, but the stock kept climbing for two more sessions as analysts digested the numbers, a reminder that “the move” isn’t always a single-day event.
Key Takeaways
- Adjusted EPS of $6.38 beat the roughly $4.91 consensus estimate by about 30%; GAAP EPS was $6.04.
- Revenue of $112.0 billion was up just 0.3% year-over-year, a deliberate trade-off for margin recovery, not a growth miss.
- Medical cost ratio (MCR) fell to 86.7%, down from 89.4% a year earlier and the lowest reading in two years.
- UnitedHealth raised full-year 2026 adjusted EPS guidance to $19.50-$20.00, up from a prior outlook of “more than $18.25.”
- Options had priced a 6.1%-6.27% expected move; the stock traded as much as 7.6% higher intraday before closing up roughly 4.6% on the day, then continued higher over the next two sessions.
The Numbers That Actually Moved the Stock
UnitedHealth reported Q2 2026 results before the market open on Thursday, July 16, per the company’s own SEC 8-K filing. Adjusted (non-GAAP) earnings per share came in at $6.38 against a Wall Street consensus in the $4.85-$4.91 range depending on the data provider, a beat of roughly 30%. GAAP EPS was $6.04. Earnings from operations were $8.0 billion, up from $5.2 billion in the same quarter a year ago, a sign the recovery is showing up in actual operating results, not just accounting adjustments.
Revenue was $112.0 billion, ahead of the roughly $110.6-$110.9 billion analysts expected, but up only 0.3% year-over-year. For a company UnitedHealth’s size, flat revenue usually reads as a red flag. Here it’s closer to the opposite: management has been intentionally trading some membership growth and pricing aggressiveness for underwriting discipline after a brutal 2025, and the near-flat top line paired with a sharply better cost ratio is exactly what that discipline is supposed to look like on paper.
Why Medical Cost Ratio Is the Number That Actually Drives This Stock
Medical cost ratio (also called medical loss ratio, or MCR) is the share of premium revenue an insurer pays out in medical claims. A lower MCR means more of every premium dollar falls to the bottom line. UnitedHealth’s Q2 2026 MCR was 86.7%, down from 89.4% in the year-ago quarter, which the company attributed to cost and pricing discipline plus a favorable mix shift across its benefit offerings.
This is the single metric that separates UnitedHealth’s earnings-day setup from almost everything else in a typical options trader’s earnings calendar. Bank earnings move on net interest margin and trading revenue. Asset managers move on AUM and fee rates. UnitedHealth moves on how well it priced and managed medical claims relative to the premiums it collected, a completely different mechanism, and one that’s much harder to forecast from the outside because it depends on internal actuarial assumptions that only show up once a quarter.
The Setup: Why UNH Carried Elevated Implied Volatility Into This Print
Context matters here. UnitedHealth had one of its worst operating years in company history in 2025: full-year EPS fell roughly 41% to $16.35, hit by elevated Medicare Advantage medical costs, the lingering aftermath of the Change Healthcare cyberattack, and losses inside Optum Health’s value-based care arrangements. The stock fell from above $600 in late 2024 to a low near $234 in March 2026 before bouncing to around $404 by April as investors started pricing in a turnaround.
On top of the operational reset, UnitedHealth is still facing both criminal and civil Department of Justice investigations tied to its Medicare billing practices, with no announced resolution timeline. That kind of open-ended legal overhang is exactly why options on UNH have carried a persistently elevated implied volatility premium relative to its historical norm through 2025 and into 2026: the market isn’t just pricing quarterly earnings risk, it’s pricing the chance of a headline dropping on any given day. That’s a genuinely different risk profile than a money-center bank reporting into a known regulatory environment, and it’s worth acknowledging plainly: this is not a low-drama, “check the box and move on” earnings name, and it isn’t a fit for a trader who wants a predictable, low-IV setup.
What Options Priced Going In vs. What Actually Happened
Heading into the print, options data showed the market pricing a 6.1% to 6.27% expected move for UNH, calculated the standard way: roughly 85% of the value of the at-the-money straddle (the combined price of the nearest calls and puts), which approximates a one-standard-deviation range for the stock by expiration. That priced move sat noticeably below UNH’s own trailing average post-earnings swing of about 9% to 9.7% over the prior four to eight quarters, a gap worth noting for anyone who checks a stock’s expected move on a platform like tastytrade before deciding how to size an earnings trade: the market’s priced move and a stock’s own historical move are two different numbers, and they don’t always agree.
On the day itself, UNH shares jumped as much as 7.6% in premarket trading to around $418, then settled into a smaller but still substantial close, up roughly 4.6% for the regular session. That print-day move landed inside the priced 6.1%-6.27% expected move, meaning a trader who had sold premium sized to that expected move, a short strangle or iron condor, for example, would have kept the stock inside the breakeven range on day one. But the story didn’t end there: shares closed at $426.09 on July 17, and continued higher into July 18 as several sell-side banks raised their targets for the stock into the mid-$400s to low-$500s range following the print.
That two-stage pattern, a contained print-day move followed by continued drift as analysts digest the quarter and update models, is a useful case study for anyone who trades earnings with short-dated options expecting a single clean resolution. The expected-move framework is built around the assumption that most of the uncertainty resolves in one session. Here, the initial IV crush happened on schedule, but the fundamental repricing (driven by the guidance raise and the medical cost ratio improvement, not just the headline EPS number) kept playing out for two more trading days.
| Measure | Value |
|---|---|
| Options-priced expected move (pre-earnings) | 6.1% – 6.27% |
| UNH trailing average post-earnings move (prior 4-8 quarters) | ~9% – 9.7% |
| Actual move, premarket peak | +7.6% |
| Actual move, regular-session close on report day | +4.61% |
| Cumulative move through July 17 close ($426.09) | Additional +0.64% the following session |
A Hypothetical Look at How This Might Have Been Structured
Purely as an illustration of the mechanics, and not a recommendation of any kind: a trader who wanted defined risk into this print and believed the options market’s 6.1%-6.27% expected move was a reasonable pricing of near-term risk might have considered an iron condor with short strikes placed just outside that range, collecting premium against the bet that the stock would stay inside the priced move through expiration. Given the actual print-day move landed inside that range, such a hypothetical position would have benefited from the IV crush that typically follows an earnings release. It would not, however, have accounted for the continued upward drift over the following two sessions if the position’s expiration extended that far, a reminder that “the move is over” and “the stock has stopped moving” are not the same thing. None of this is a suggestion to replicate the trade; it’s an illustration of how expected-move math is actually used, sized to what the market priced at the time.
What This Means Going Forward
The DOJ investigation remains unresolved, and that alone is likely to keep UNH’s implied volatility elevated relative to peers regardless of how clean any individual quarter looks. For traders who follow this name specifically, the medical cost ratio and forward guidance cadence, not the headline EPS beat, are the numbers worth tracking each quarter, since MCR is the metric management itself is using to signal whether the turnaround is durable or a single good print. A name with this combination of legal overhang and historically wide swings is best suited to traders who are comfortable with defined-risk structures and who size positions assuming the realized move could exceed whatever the options market has priced in, not the other way around.
Bottom Line
UnitedHealth’s Q2 2026 beat was real and driven by genuine operational improvement, not accounting noise, but the options market’s 6.1%-6.27% priced move undershot the stock’s own historical average swing even as the print-day reaction stayed inside that range. The bigger lesson is that the reaction unfolded over multiple sessions instead of a single gap, which matters for how short-dated earnings trades around this name should be sized and timed.
FAQ
Q: What was UnitedHealth’s actual EPS for Q2 2026?
A: Adjusted (non-GAAP) EPS was $6.38, versus a Wall Street consensus estimate in the $4.85-$4.91 range, a beat of roughly 30%. GAAP EPS was $6.04.
Q: Why did UNH stock jump after Q2 2026 earnings?
A: The combination of a large EPS beat, a medical cost ratio that fell to a two-year low of 86.7% (from 89.4% a year earlier), and raised full-year guidance to $19.50-$20.00 adjusted EPS drove shares up as much as 7.6% intraday before settling to a roughly 4.6% close on the report day.
Q: What is medical cost ratio and why does it matter for UNH specifically?
A: Medical cost ratio (MCR) measures the share of premium revenue an insurer pays out in medical claims. A lower MCR means more premium dollars fall to the bottom line. It’s the primary driver of UnitedHealth’s earnings-day moves, distinct from the metrics that move banks (net interest margin) or asset managers (AUM and fee rates).
Q: What expected move did options traders price ahead of UNH’s Q2 2026 report?
A: Options data showed a priced expected move of roughly 6.1% to 6.27%, calculated from the at-the-money straddle, below UNH’s own trailing average post-earnings move of about 9% to 9.7% over the prior several quarters.
Q: Is UnitedHealth’s DOJ investigation still a risk factor for the stock?
A: Yes. The company continues to face both criminal and civil Department of Justice investigations related to Medicare billing practices, with no announced resolution timeline as of this report. That open-ended legal risk is a likely reason UNH options have carried elevated implied volatility relative to its own historical norm.
Keep learning: For more on how options traders read earnings-week volatility across an entire sector rather than a single name, see our breakdown of options pricing heading into the summer 2026 earnings cluster, or browse the full Market Analysis archive for more earnings recaps like this one.